Description
Research Overview
Semax is a synthetic heptapeptide composed of Met-Glu-His-Phe-Pro-Gly-Pro and is derived from a fragment of adrenocorticotropic hormone (ACTH). It has been investigated in experimental research involving neuropeptide signalling, neuronal function, gene expression and central nervous system processes.
Research Focus
Research has examined Semax in relation to neurotrophin expression, inflammatory signalling, neuronal responses and molecular pathways associated with cerebral ischemia. Experimental studies have investigated changes in gene and protein expression following Semax exposure, including pathways associated with neurotrophic and immune responses.
Scientific Context
A substantial portion of the available Semax literature consists of preclinical research, including cellular and animal models examining neurological and molecular mechanisms. Experimental studies have reported changes in neurotrophin-related gene expression and inflammatory pathways, but findings from these models cannot by themselves establish clinical efficacy in humans.
Important Research Note
Semax remains an investigational research compound in this context. The available evidence varies by study design and population, and research findings should not be interpreted as evidence that Semax is safe or effective for cognitive enhancement, neuroprotection, stroke recovery, neurological disease or any other human application.
For research purposes only. Not intended for human or veterinary use.
